VTP-600 is under clinical development by Barinthus Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VTP-600’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VTP-600 overview

VTP-600 is under development for the treatment of non-squamous  non-small cell lung cancer, squamous oesophageal cancer, squamous non-small cell lung cancer. It is a recombinant vector vaccine developed based on chimpanzee adenovirus technology. It is administered through intravenous route. It is a comprised of two vectors ChAdOx1 and Modified Vaccinia Ankara engineered to express the tumour-associated antigens MAGE-A3 and NY-ESO-1.

Barinthus Biotherapeutics overview

Barinthus Biotherapeutics (Barinthus), formerly Vaccitech plc, is a clinical-stage biopharmaceutical company that develops novel T-cell immunotherapeutic candidates. The company’s pipeline products include VTP-300: Hepatitis B, VTP-200: Human Papillomavirus, VTP-800/850: Prostate Cancer Therapeutic, VTP-600: Cancer, VTP-1000: Celiac Disease, VTP-1100: HPV Cancer, VTP-900: Covid-19, VTP-500: MERS Prophylactic, VTP-400: Zoster Prophylactic. Its proprietary platforms, ChAdOx, MVA, and SNAPvax, are designed to harness the power of the immune system’s T cells and can be combined in prime-boost regimens, providing advantages in terms of tolerability, manufacturability and efficacy. Barinthus is headquartered in Didcot, England, the UK.

For a complete picture of VTP-600’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.